CXCR1 and melanoma: SX-682 is another novel potent inhibitor of CXCR1/2 (22, 71) and recently being investigated in many clinical trials in several cancer types such as melanoma, colorectal cancer, and breast cancer (NCT03161431, NCT04574583, and NCT04245397).